Description

5mg Cagrilintide Vial

5mg Cagrilintide Research Peptide | Research Use Only

Cagrilintide is a long-acting synthetic amylin analogue that is being extensively investigated in metabolic and obesity-related research. The 5mg Cagrilintide vial is intended for qualified research applications involving appetite regulation, energy balance, metabolic pathways, and amylin receptor biology.

Cagrilintide has been studied both as a standalone investigational compound and in combination with semaglutide in clinical research. Novo Nordisk describes cagrilintide as a long-acting amylin analogue and continues to investigate it in clinical programmes involving overweight, obesity, and type 2 diabetes.

Product Highlights

• Product: Cagrilintide

• Quantity: 5mg per vial

• Compound type: Long-acting amylin analogue

• Format: Research peptide vial

• Intended application: Laboratory and scientific research

• Use: Research use only

• Not intended for: Human or veterinary use, diagnosis, treatment, cure, or prevention of disease

Cagrilintide Research Applications

Cagrilintide is of interest in research investigating the biological pathways associated with amylin signalling, appetite regulation, satiety, food intake, and metabolic function.

Research involving cagrilintide has included investigation of its potential role in weight-management and metabolic-disease pathways. Clinical studies have also examined cagrilintide alongside semaglutide as part of the investigational CagriSema programme.

Why Choose a 5mg Cagrilintide Vial?

A 5mg presentation provides researchers with a clearly defined quantity of cagrilintide for laboratory research and analytical applications. Researchers should follow their institution’s applicable procedures for storage, handling, preparation, and experimental use.

Order 5mg Cagrilintide for Research

Oak Peptides Pharmaceuticals provides research compounds for qualified laboratory and scientific applications. For product availability, specifications, and ordering information, contact our team directly.